real production cost, page-7

http://www.heartware.com.au/irm/Company/ShowPage.aspx?CPID=1327 Capital Structure
HeartWare presently has 8,866,702 shares of common stock on issue and these are represented by
309,092,210 CDI’s which are tradeable on the ASX (being a ratio of one share of common stock to 35
CDI’s). Following listing on NASDAQ, it is expected that some investors, particularly our US
investors, will migrate their holdings from Australia to the United States by exchanging their CDI’s
for common stock.
In this regard, HeartWare’s stock is very tightly held with approximately 80% of the shares being held
by investors located in the United States. Our four largest shareholders, Apple Tree Partners, Muneer
Satter, Fidelity Investments and Deephaven Capital Management, account for approximately 60% of
HeartWare’s issued capital. The remaining 20% of US-owned stock is held primarily by specialist
healthcare funds including Eaton Vance, Redmile Group, Broadfin Capital and others.
US investor interest in the HeartWare story continues to grow. HeartWare believes that listing on
NASDAQ will help to deepen the already strong institutional presence on the Company’s share
register.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or Left
Ventricular Assist Devices (LVADs), to treat patients suffering from advanced heart failure.
HeartWare’s HVAD™ pump is the only full-output pump designed to be implanted in the chest,
avoiding the abdominal surgery generally required to implant competing devices. HeartWare has
completed an international clinical trial for the device involving five investigational centres in Europe
and Australia. The device is currently the subject of a 150-patient clinical trial in the United States for
a Bridge-to-Transplant indication.
For further information:
www.heartware.com.au US Investor Relations
Howard Leibman Matt Clawson
Director Corporate Development Partner
HeartWare Limited Allen & Caron, Inc.
Email. [email protected] Email. [email protected]
Tel. +61 2 9238 2064 Tel. +1 949 474 4300
Forward-Looking Statements
This announcement contains forward-looking statements that are based on management’s beliefs,
assumptions and expectations and on information currently available to management. All statements
that address operating performance, events or developments that we expect or anticipate will occur in
the future are forward-looking statements, including without limitation our expectations with respect
to the progress of clinical trials. Management believes that these forward-looking statements are
reasonable as and when made. However, you should not place undue reliance on forward-looking
statements because they speak only as of the date when made. We do not assume any obligation to
publicly update or revise any forward-looking statements, whether as a result of new information,